The pathogenesis of bilirubin encephalopathy seems to result from accumulation of unconjugated bilirubin (UCB) within the brain. We have recently demonstrated that UCB causes astroglial release of proinflammatory cytokines and glutamate, as well as cell death. The bile acid glycoursodeoxycholic acid (GUDCA) and the anti-inflammatory cytokine interleukin (IL)-10 have been reported to modulate inflammation and cell survival. In this study we investigated the effect of these therapeutic agents on the astroglial response to UCB. Only GUDCA prevented UCB-induced astroglial death. The secretion of tumor necrosis factor-> (TNF->) and IL-1A elicited by UCB in astrocytes was reduced in the presence of GUDCA and IL-10, whereas the suppression of IL-6 was only counteracted by GUDCA. Neither GUDCA nor IL-10 modulated the accumulation of extracellular glutamate. Additionally, IL-10 markedly inhibited UCB-induced nuclear factor-JB nuclear translocation and cytokine mRNA expression, whereas GUDCA only prevented TNF-> mRNA expression. Moreover, GUDCA inhibited TNF->-and IL-1A-converting enzymes, preventing the maturation of these cytokines and their consequent release. Collectively, this study shows that IL-10 action is restricted to UCB-induced release of TNF-> and IL-1A from the astrocytes, whereas GUDCA presents a more ubiquitous action on the astroglial reactivity to UCB. Hence, GUDCA may have potential benefits over an IL-10 therapeutic approach in reducing UCB-induced astrocyte immunostimulation and death.
INTRODUCTION
Nerve cell injury induced by unconjugated bilirubin (UCB) has been implicated in brain damage during neonatal hyperbilirubinemia. Although the primary target of UCB neurotoxicity is still not known, our previous results suggested that UCB toxicity in cultured astrocytes and neurons may be attributed to alterations in cell membranes (1) and impairment of the crucial aspects of cell function (2Y4). Exposure of astrocytes to UCB also elicits the accumulation of extracellular glutamate by decreased uptake (5) and/or enhanced secretion (6) .
Although the proinflammatory function of astroglia is less prominent than that of microglia (7), astrocytes have been described as becoming activated and mounting an inflammatory response to several brain insults (8) . In this regard, UCB, at clinically relevant concentrations, induces the expression of tumor necrosis factor-> (TNF->) and interleukin (IL)-1A mRNAs and the secretion of TNF->, IL-1A, and IL-6 by astrocytes (6, 9) . This activation occurs through the engagement of the nuclear factor JB (NF-JB) and the mitogenactivated protein kinase pathways (10) . Thus, blockade of the signaling cascades involved in the release of cytokines and cell dysfunction by UCB may provide new data on potential therapeutics to be used in the prevention of UCB-induced brain injury.
Glycoursodeoxycholic acid (GUDCA) is the major species (79.8%) resulting from the oral administration and consequent hepatic glycine conjugation of ursodeoxycholic acid (UDCA), a well-known bile acid used for the treatment of hepatobiliary disorders (11, 12) . Interestingly, GUDCA was also shown to have neuroprotective effects through the prevention of mitochondrial swelling and cytochrome c release elicited by 3-nitropropionic acid in rat neuronal RN33B cells (13) . In addition, either the taurine conjugated species, tauroursodeoxycholic acid (TUDCA) or UDCA also have antiapoptotic properties (13Y18). Moreover, UDCA exerts diverse immunomodulatory actions (19Y22), and, consequently, has been used for a long time in the treatment of primary biliary cirrhosis to correct the related immunologic abnormalities (23) .
IL-10 is an important immunoregulatory cytokine produced by many cell types (24) . Recent data suggest that both astrocytes and microglia are able to physiologically synthesize and secrete IL-10 (25). IL-10 was shown to act on astroglial and microglial cells (26) , suppressing cytokine production induced by inflammatory agents (27, 28) . Thus, human recombinant IL-10 is being tested as a therapeutic agent for autoimmune and inflammatory-associated diseases (24) .
The present study was designed to evaluate the effects of GUDCA and IL-10 on UCB-induced astrocyte death and accumulation of extracellular glutamate, as well as on astrocyte reactivity to UCB regarding the molecular mechanisms of cytokine induction, their expression, and consequent release. Our data show that only GUDCA prevents the astroglial cell death triggered by UCB, whereas neither GUDCA nor IL-10 is able to reduce the release of glutamate. Additionally, GUDCA inhibits the secretion of TNF-> and IL-1A and counteracts the suppression of IL-6 secretion elicited by UCB after a 4-hour incubation period, whereas IL-10 abrogates the production of all the cytokines studied. Interestingly, whereas IL-10 immunosuppressive action occurs through the blockade of NF-JB activation and cytokine mRNA expression, GUDCA presents a distinct intracellular action by maintaining NF-JB nuclear translocation and partially preventing TNF-> mRNA expression when astrocytes are simultaneously exposed to UCB and GUDCA. In subsequent studies, GUDCA was shown to increase the intracellular levels of pro-TNF-> and pro-IL-1A that were reduced by UCB. Moreover, the UCB-stimulated activation of TNF->-and IL-1A-converting enzymes (TACE and ICE, respectively) responsible for converting the cytokine pro-forms into the active ones, is prevented by GUDCA. In sum, by preventing the astroglial demise and reestablishing the astrocyte function, GUDCA appears to be a more beneficial therapy than IL-10 against the risk and/or progression of brain disabilities after severe or lasting hyperbilirubinemia.
MATERIALS AND METHODS

Reagents and Media
Dulbecco_s modified Eagle_s medium and fetal calf serum were purchased from Biochrom AG (Berlin, Germany). Antibiotic antimycotic solution (20Â), bovine serum albumin, human serum albumin (HSA) (fraction V, fatty acid free), Hoechst dye, mouse antibody anti-A-actin, and goat antibody anti-rabbit labeled with fluorescein isothiocyanate were acquired from Sigma Chemical Co (St. Louis, MO). UCB was also obtained from Sigma and purified according to the method of McDonagh (29) . A concentrated solution of 5 mM GUDCA (minimum 96% pure; Calbiochem, Darmstadt, Germany) was prepared in sterile PBS and a stock solution of 50 Kg/mL of recombinant rat IL-10 (R&D Systems, Minneapolis, MN) was prepared in sterile PBS containing 0.1% HSA. DuoSet ELISA Kits, as well as primary specific monoclonal antibodies, goat anti-TNF-> and goat anti-IL-1A, were also from R&D Systems. The lactate dehydrogenase (LDH) cytotoxicity detection kit and L-glutamic acid kit were purchased from Roche Molecular Biochemicals (Mannheim, Germany). TRIzol reagent and primer pairs were from Invitrogen (Carlsbad, CA), the reverse transcriptase (RT)-polymerase chain reaction (PCR) core reagents kit was from Promega (Madison, WI) and Biomax MR Film was from Kodak Industries (Cedex, France Rat primary astrocyte cultures were prepared from cerebral cortices of 2-day-old Wistar rats as described previously (30) , with minor modifications (5, 10) . The protocol resulted in highly pure astrocyte cultures (996%) with absence of neurons and a minor contamination of microglia (G2.5%) and oligodendrocytes (G1.5%), as assessed by immunocytochemical staining using primary antibodies raised against glial fibrillary acidic protein of astrocytes, neurofilaments of neurons, the CR3 complement receptor of microglia, OX-42, and myelin basic protein of oligodendrocytes.
Cell Treatment
Astroglial cultures were stimulated after 10 days in culture with 50 or 100 KM UCB or vehicle alone, in the presence of 100 KM HSA for 4 hours at 37-C. A 10 mM UCB stock solution in 0.1 M NaOH was prepared immediately before use. Appropriate dilutions were made and the pH of the incubation medium was restored to 7.4 by the addition of equal amounts of 0.1 M HCl. All the experiments with UCB were performed under light protection to avoid photodegradation.
In coincubation studies, cells were pretreated for 1 hour with 50 KM GUDCA or 10 ng/mL recombinant rat IL-10 before the addition of 50 or 100 KM UCB to the same medium. Appropriate controls including cells treated with GUDCA, IL-10, or vehicle alone were also included. The dose of GUDCA was chosen on the basis of the literature to mimic as much as possible the physiologic bile acid level present in the serum of patients treated with 450 to 600 mg/day UDCA (31, 32) , a concentration that has been demonstrated to have a protective action without affecting cell viability (33, 34) . The concentration of IL-10 was selected according to information previously reported in the literature for comparative in vitro studies between different immunosuppressive agents (27, 28) .
After treatment, the cell-free medium was collected for LDH, cytokine, and glutamate measurements, and attached cells were either lysed for immunoblotting studies or fixed for 30 minutes with freshly prepared 4% paraformaldehyde in PBS for immunocytochemical studies and apoptosis evaluation.
Cell Death
Standard evaluation of cytotoxicity was performed by measuring the LDH released by nonviable cells, as well as by assessment of the number of apoptotic cells. LDH activity was determined in the incubation medium using the cytotoxicity detection kit as described previously (35) . All readings were corrected for the possible interference of UCB absorption, and the results are expressed as a percentage of LDH release, obtained by treating nonincubated cells with 2% Triton X-100 for 30 minutes. Apoptosis was evaluated by assessment of nuclear morphology of astrocytes by Hoechst staining as described previously (34) . Fluorescence was visualized using a Leica DC 100 camera (Leica, Wetzlar, Germany) adapted to an Axioskop microscope (Zeiss, Göttingen, Germany), categorized according to condensation and staining characteristics of chromatin, and scored by investigators blinded to the treatment received by cells. Apoptotic nuclei were identified by condensed chromatin contiguous to the nuclear membrane, as well as nuclear fragmentation of condensed chromatin. Five random microscopic fields (original magnification: 516Â) per sample were counted (~400 cells per sample), and mean values are expressed as percentages of apoptotic nuclei.
Measurement of Cytokine Production
Aliquots of the cell culture supernatants, collected at the end of the incubations, were placed in a 96-well microplate and assessed in duplicate for TNF->, IL-1A, and IL-6 with specific DuoSet ELISA Development Kits from R&D Systems, according to the manufacturer_s instructions. Results are expressed as picograms per milliliter.
Measurement of Glutamate Release
Release of glutamate to culture medium was determined by an adaptation of the L-glutamic acid kit, using a 10-fold reduction in kit reagents. The reaction was performed in a 96-well microplate, and the absorbance was measured at 490 nm using a reference filter of 620 nm. A calibration curve was used for each assay, and results are expressed as micromolar concentrations.
Detection of NF-JB Activation
For immunofluorescence detection of NF-JB, cells were fixed as described above, and a standard immunocytochemical technique was performed using a polyclonal rabbit anti-p65 NF-JB subunit antibody (1:200) as the primary antibody and a fluorescein isothiocyanate-labeled goat anti-rabbit antibody (1:160) as the secondary antibody. To identify the total number of cells, astroglial nuclei were stained with Hoechst dye 33258 as described previously (34) . Fluorescence was visualized using a Leica DC 100 camera adapted to an Axioskop microscope. Pairs of ultraviolet and green fluorescence images of 5 random microscopic fields (original magnification: 516Â) were acquired per sample. NF-JB-positive nuclei, identified by localization of the NF-JB p65 subunit staining exclusively at the nucleus, and total cells were counted (~400 cells per sample) to determine the percentage of NF-JB-positive nuclei.
Semiquantitative Reverse Transcriptase-Polymerase Chain Reaction
For determination of mRNA cytokine expression, total RNA was extracted from astrocytes using the TRIzol reagent. For RT-PCR, 1 Kg of total RNA was reversetranscribed as described previously (9) using the RT-PCR Core Reagents kit. Specific oligonucleotide primer pairs were incubated with a cDNA template for PCR amplification using the above-mentioned kit. The PCR products (5 KL) were electrophoresed on a 5% polyacrylamide gel, and dried gels were exposed to a Kodak Biomax MR Film. The following sequences were used as primers: TNF-> sense, 
Western Blot Assay
The intracellular forms of TNF-> and IL-1A were determined by Western blot analysis as usual in our laboratory (9) . Briefly, total protein was extracted from primary astrocytes using the Lysis buffer from Cell Signaling, and 50 Kg were separated on a 10% sodium dodecyl sulfatepolyacrylamide electrophoresis gel. After electrophoretic transfer onto a nitrocellulose membrane and blocking with 5% milk solution, the blots were incubated with primary antibody overnight at 4-C (anti-TNF-> 
Enzyme Activities Determination
After incubation adherent cells were washed in PBS, and total cell extracts were obtained by lysing cells in specific icecold lysis buffers for 30 minutes on ice. Cells were lysed in buffer A (10 mM Tris-HCl, 10 mM NaH 2 PO 4 /NaHPO 4 [pH 7.5], 130 mM NaCl, 1% [v/v] TritonX-100, and 10 mM NaPPi) for TACE measurement and in buffer B (250 mM HEPES [pH
, and 25 mM dithiothreitol) for ICE measurement. The lysate was centrifuged at 16,000 Â g for 10 minutes at 4-C, and the supernatants were collected and stored at Y80-C. Protein concentrations were determined as mentioned above before enzyme activity evaluation.
The activity of TACE was determined in cell lysates by enzymatic separation of the fluorophore o-aminobenzoyl (Abz) and the quencher 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionic amide (Dpa) present in the substrate Abz-LAQAV RSSSR-Dpa, leading to an increase of fluorescence (36) . The proteolytic reaction was carried out in protease assay buffer (50 mM Tris-HCl [pH 7.4], 25 mM NaCl, and 4% [v/v] glycerol) containing 5 mg/mL substrate. After incubation of the reaction mixtures for 1 hour at room temperature, fluorescence was monitored at L ex = 320 nm and L em = 420 nm.
The activity of ICE was determined in cell lysates by enzymatic cleavage of the chromophore p-nitroanilide (pNA) from the substrate Ac-YVAD-pNA (37) . The proteolytic reaction was carried out in protease assay buffer (200 mM HEPES [pH 7.5], 1% [w/v] CHAPS, 50 mM dithiothreitol, 20 mM EDTA, and 50% [w/v] sucrose) containing 2 mM substrate. After incubation of the reaction mixtures for 1 and 2 hours at 37-C, the formation of pNA was monitored at 405 nm with a reference filter of 620 nm.
Densitometry and Statistical Analysis
The relative quantities of nucleic acid and protein bands were analyzed using Gel-Pro Analyser densitometric analysis program (version 4.5; Media Cybernetics, San Diego, CA), after scanning into Adobe Photoshop. Significant differences between 2 groups were determined by 1-way analysis of FIGURE 1. Glycoursodeoxycholic acid (GUDCA) (50 KM) is able to reduce both lactate dehydrogenase (LDH) release (A) and apoptosis (B) of cells exposed to unconjugated bilirubin (UCB) in contrast to interleukin-10 (IL-10) (10 ng/mL), which shows no ability to prevent UCB-induced astroglial death. Determination of released LDH was performed in incubation medium. Cells were fixed and nuclei were stained for morphologic evaluation of apoptosis. Data are means T SEM from 4 independent experiments performed in duplicate. *, p G 0.05; **, p G 0.01, compared with vehicle. §, p G 0.05 compared with UCB alone. variance using the software InStat (version 3.05; GraphPad Software, San Diego, CA), and statistical significance was established when p G 0.05.
RESULTS
GUDCA Decreases Unconjugated Bilirubin-Induced Cell Death, Whereas IL-10 Has No Effect
Previous in vitro studies have confirmed that UCB induces mixed features of cell death in cultured astrocytes (6, 38, 39) . As shown in Figure 1 , UCB induced a concentration-dependent loss in astrocyte viability, presenting an approximate 2-fold increase from control values either for LDH release or apoptosis (p G 0.01). Because UDCA was previously demonstrated to inhibit UCB-induced neuronal and astroglial apoptosis (3) and GUDCA was demonstrated to reduce mitochondrial release of cytochrome c in rat neuronal RN33B cells (13) and cholangiocytes (40) after an apoptotic stimulus, we decided to investigate the ability of GUDCA to protect UCB-induced cell death in the present work model. The data clearly demonstrate that GUDCA was able to prevent not only UCB-induced release of LDH by 970% (p G 0.05) (Fig. 1A) but also astroglial apoptosis by 950% (p G 0.05) (Fig. 1B) . IL-10 has been reported to prevent cell death by blocking the expression and/or activity of pro-apoptotic inducers (41) . However, in the present study, IL-10 was not able to reduce apoptosis or LDH release (Fig. 1) , thus showing no protective action regarding UCB-induced cell death.
Both Glycoursodeoxycholic Acid and IL-10 Prevent Unconjugated Bilirubin-Induced Release of TNF-> and IL-1A, Whereas Only GUDCA Counteracts Unconjugated Bilirubin Suppression of IL-6 Secretion
In previous experiments, we have demonstrated that significant levels of the proinflammatory cytokines TNF-> and IL-1A are released from cultured rat astrocytes after a short exposure to UCB, whereas IL-6 secretion is markedly prevented (6) . Indeed, as demonstrated in Figure 2 , although vehicle-treated astrocytes were shown to release TNF->, IL-1A, and IL-6, probably owing to a basal astroglial immune response to HSA, stimulation of these cells with UCB for 4 hours resulted in a concentration-dependent increase of TNF-> (1.6-fold for 50 KM, p G 0.05, and 1.9-fold for 100 KM, p G 0.01) and IL-1A (1.6-fold for 50 KM UCB, p G 0.05, and 2.0-fold for 100 KM UCB, p G 0.01) production and in a reduction of IL-6 release (0.6-fold for 50 KM UCB, p G 0.05, and 0.5-fold for 100 KM UCB, p G 0.01). On the basis of previous reports demonstrating that UDCA has immunomodulatory properties (19, 22) , we then investigated whether GUDCA was able to modulate astroglial inflammatory response induced by UCB after 4 hours of exposure. In these conditions we avoid excessive cell death (6, 9) ,which might compromise the secretion/ production of cytokines. When UCB and GUDCA were combined in the culture medium, both TNF-> ( Fig. 2A) and IL-1A (Fig. 2B) secretions were reduced by 990% and 980% (p G 0.05), respectively, whereas the inhibition of IL-6 production by UCB was counteracted (Fig. 2C) , restoring this cytokine to basal levels. Because the anti-inflammatory cytokine IL-10 is known to regulate the production of inflammatory mediators by glial cells (27) , we decided to test its immunosuppressive properties on UCB action. IL-10 inhibited TNF-> and IL-1A production in astrocytes exposed to both concentrations of UCB to levels below control values (p G 0.01), showing higher cytokine suppression ability than GUDCA. Astroglial secretion of IL-6 by HSA was also reduced by IL-10 (960%, p G 0.01), whereas no changes were observed relative to the suppression of IL-6 produced by UCB.
Neither GUDCA nor IL-10 Prevents Unconjugated Bilirubin-Induced Accumulation of Extracellular Glutamate
Earlier studies have implicated glutamate in the braindamaging action of UCB (42, 43) . Accordingly, we have previously reported that exposure of astrocytes to UCB markedly increases the extracellular concentration of glutamate by decreased uptake (5) and/or enhanced secretion (6) . Accumulation of extracellular glutamate may also occur after cell death due to the leakage of intracellular components. Recently, impaired glutamate regulation was shown to be correlated with the presence of an inflammatory response (44) , resulting in an exacerbation of neuronal damage (45) . Hence, we sought to test whether GUDCA or IL-10, which reduced the UCB-induced astroglial death and/or cytokine release, respectively, would prevent the extracellular accumulation of glutamate observed after exposure to UCB. The results clearly indicate that neither GUDCA nor IL-10 inhibited UCB-induced extracellular glutamate accumulation (Fig. 3) . Thus, the mechanism of glutamate secretion during the exposure of astrocytes to UCB appears to not be mediated by cell death or inflammation and, therefore, no beneficial effect was produced by the modulators used in this study.
IL-10 Prevents Unconjugated Bilirubin-Induced Nuclear Factor-JB Nuclear Translocation, Whereas GUDCA Has No Effect
We have recently reported that interaction of UCB with astrocytes leads to the activation and consequent nuclear translocation of the transcription factor NF-JB, which is essential for UCB-induced cytokine release (9, 10) . Having verified that both GUDCA and IL-10 are able to inhibit UCB-induced TNF-> and IL-1A production, it became important to evaluate whether this effect results from inactivation of this signaling pathway. As shown in Figure 4 , although the p65 NF-JB subunit was localized throughout the cytoplasm with a weaker signal in the nucleus in vehicle-treated cells, stimulation with UCB induced a marked nuclear translocation of NF-JB (3.8-fold, p G 0.01), which was independent from the concentration of UCB used. Incubation with GUDCA alone also induced NF-JB nuclear translocation (4.7-fold, p G 0.01), in a level that was maintained when cells were coincubated with UCB. However, IL-10 inhibited UCB-induced NF-JB activation by approximately 70% (p G 0.01) and 50% (p G 0.05) for 50 and 100 KM UCB, respectively. This finding suggests that suppression of UCB-induced cytokine release by IL-10 occurs through blocking of NF-JB activation, whereas GUDCA exerts its modulatory action at a distinct stage of cytokine production.
IL-10 Prevents Unconjugated
Bilirubin-Stimulated TNF-> and IL-1A mRNA Expression, Whereas GUDCA Only Reduces TNF-> mRNA
Having observed that IL-10 and GUDCA prevent the immunostimulant effect of UCB on astrocyte cultures but that only IL-10 is able to block the UCB-induced NF-JB nuclear translocation, we decided to investigate the action of these agents on the subsequent stages that lead to cytokine secretion. In a previous study, we have demonstrated that UCB induces the mRNA expression of proinflammatory cytokines (9) . As shown in Figure 5 , astroglial levels of TNF-> and IL-1A mRNAs were increased after a 4-hour exposure to UCB (~1.3-fold for TNF-> and~1.2-fold for IL-1A, p G 0.01) when compared with vehicle. GUDCA alone induced the mRNA expression of IL-1A, although less markedly than UCB and was only able to reduce UCBstimulated TNF-> expression (p G 0.05) in coincubation experiments (Fig. 5) , suggesting that its immunosuppressive action would also occur downstream from the transcriptional level of cytokine production. As expected, cotreatment of astrocytes with UCB and IL-10 prevented the mRNA expression of both TNF-> and IL-1A to levels below vehicle values (p G 0.01), which is in accordance with its inhibitory effect on NF-JB activation by UCB.
Astroglial TNF-> and IL-1A Pro-Forms Are Reduced by Unconjugated Bilirubin But Markedly Increased by GUDCA Owing to its Inhibition of Unconjugated Bilirubin-Stimulated TNF->-and IL-1A-Converting Enzyme Activity Upon transcription, cytokine proteins are synthesized as inactive or precursor forms (pro-forms), and must undergo a process of cleavage to originate the mature/active forms, which are consequently secreted to the extracellular FIGURE 6. Astrocyte intracellular levels of tumor necrosis factor (TNF)-> and interleukin (IL)-1A pro-forms are reduced by unconjugated bilirubin (UCB), but increased during coincubation with glycoursodeoxycholic acid (GUDCA) (50 KM). In addition, UCB increases TNF->-converting enzyme (TACE) and IL-1A-converting enzyme (ICE) activities, which are abrogated in the presence of GUDCA. Total cell lysates were analyzed by Western blotting with specific antibodies for TNF-> (A) and for IL-1A (B). Representative results from 1 experiment are shown. Similar results were obtained in 3 independent experiments. The intensity of the bands was quantified by scanning densitometry, normalized with respect to endogenous A-actin and expressed as fold change compared with control. The activities of TACE (C) and ICE (D) were determined in total cell extracts using fluorometric and colorimetric kits, respectively. Results are mean T SEM from 3 independent experiments performed in duplicate. *, p G 0.05; **, p G 0.01, compared with vehicle; §, p G 0.05; § §, p G 0.01, compared with UCB alone. media (46) . Because GUDCA has been shown to affect UCB-stimulated mRNA expression of TNF-> but not that of IL-1A, we then evaluated the intracellular levels of these proinflammatory cytokines by Western blotting. Interestingly, we only detected the presence of 1 band each for either TNF-> or IL-1A in total cell lysates, which, by their molecular weights, corresponded to the pro-forms of these cytokines (Fig. 6A, B) . Exposure of astrocytes to UCB led to a reduction in pro-TNF-> (~20%, p G 0.01) and in pro-IL-1A (~25%, p G 0.05) levels compared with vehicle values (Fig. 6A, B) . This decline of the cytokine pro-forms is in accordance with an increase of mature TNF-> and IL-1A and their consequent release observed after UCB incubation. In contrast, coincubation with GUDCA resulted in a marked increase in both cytokine pro-forms (~60% for TNF-> and 75% for IL-1A, p G 0.01).
Because the activation process of the pro-forms of TNF-> and IL-1A is mediated by the specific enzymes TACE and ICE, respectively, we evaluated the action of either UCB and/or GUDCA on their activity. As shown in Figure 6C and D, UCB promoted an increase in both TACE and ICE activities after a 4-hour incubation (~1.7-fold for TACE and~1.5-fold for ICE, p G 0.05). It is worthwhile to note that coincubation with GUDCA almost completely abrogated the UCB-stimulated increase of both enzyme activities (~90%, p G 0.05 for TACE and~100% for ICE, p G 0.01), corroborating our hypothesis that GUDCA is preventing UCB-induced astroglial release of proinflammatory cytokines by inhibiting TNF-> and IL-1A maturation.
DISCUSSION
In the present study, we evaluated the effects of GUDCA and IL-10 on the reactivity of astrocyte cultures to UCB in conditions that mimic moderate to severe hyperbilirubinemia and that have been shown to induce an inflammatory response and 10% cell death (6, 47) . Although no studies have directly connected an inflammatory response with the UCB encephalopathy, the presence of inflammation features, namely fever episodes and brain edema, have been consistently described in the literature (48, 49) . Here, we provide evidence that GUDCA and IL-10, although both demonstrating a suppressive action over the UCB-induced astroglial inflammatory response, act through distinct intracellular mechanisms and have different effects on UCBinduced cell death.
In the present work we demonstrated that the mixed features of astroglial death induced by UCB can be prevented by GUDCA, a bile acid with antiapoptotic properties (16, 17) . We previously reported that UCBinduced apoptosis of neuronal cells is prevented when UDCA or its taurine-conjugated derivative is combined with UCB (3, 50) . The present results show that GUDCA is also able to reduce UCB-induced astroglial apoptosis, possibly through similar antiapoptotic mechanisms. Interestingly, we also demonstrate that GUDCA is very effective in the prevention of UCB-induced LDH release. Recent studies revealed that UDCA induces intracellular survival pathways (51) by the stimulation of surface receptors (16) . It is then possible that, in our experimental conditions, GUDCA may also prevent UCB-induced astroglial cytotoxicity by stimulating survival cascades. Because of its immunomodulatory properties (19) , UDCA has been used to correct immunologic abnormalities observed in primary biliary cirrhosis (23) . Here, we also present evidence that GUDCA prevents the inflammatory effect of UCB, while counteracting the inhibition of IL-6 production.
The anti-inflammatory cytokine IL-10 is synthesized and secreted by glial cells under physiologic (25) and especially under inflammatory conditions (28) , regulating the local production of inflammatory mediators (27) . Nevertheless, we did not find any detectable amount of IL-10 after a 4-hour exposure of astrocytes to UCB (data not shown). Recent studies indicate also that IL-10 plays a crucial role in the survival of nerve cells, including astrocytes (41) , by blocking the expression and/or activity of proapoptotic inducers. We therefore investigated the ability of exogenous recombinant IL-10 to inhibit UCB-induced cell death. Even though IL-10 could easily suppress TNF-> and IL-1A release below control levels, cytokines that we showed to induce astroglial cell death (9) and restrain IL-6 secretion elicited by UCB, it failed to prevent cell death by UCB. Thus, the above results point out that UCB cytotoxicity is not entirely dependent from cytokines, and other factors or mechanisms are surely present.
In vivo studies have implicated glutamate excitotoxicity in UCB-induced brain injury (43) , whereas in vitro studies showed increased neuronal apoptosis via activation of the NMDA glutamate receptors in the presence of UCB (42) . Our previous data demonstrated that during UCBinduced release of cytokines and cell death (6), there is also accumulation of extracellular glutamate (6) . Interestingly, Bezzi et al (45) demonstrated that TNF-> is essential for glutamate release from astrocytes, whereas others showed that TNF-> and IL-1A decreased astrocyte glutamate transporter activity (44) . In addition, IL-6 has been reported to inhibit glutamate release in rat cerebral cortex (52) and to protect neurons from glutamate toxicity (53) . Therefore, it would be expected that a combination of UCB with GUDCA or IL-10, which inhibits UCB-induced inflammatory response, would also modulate accumulation of extracellular glutamate after UCB exposure. However, our data clearly indicate that both GUDCA and IL-10 have no effect on glutamate concentration, suggesting that this phenomenon occurs by a distinct mechanism, independent of cytokine production. In accordance, no alteration was found on the basal levels of extracellular glutamate when astrocytes were stimulated with TNF->, IL-1A, or IL-6 at levels similar to those detected after UCB treatment (data not shown).
In vitro studies demonstrated that IL-10 inhibits inflammatory cytokine gene expression by preventing NF-JB translocation to the nucleus (54, 55) . Accordingly, in our study, IL-10 markedly abrogated NK-JB activation by UCB, a pathway that is involved in UCB-induced cytokine production (9) . Additionally, the abrogation of the UCBstimulated increase of TNF-> and IL-1A mRNA expression by IL-10 corroborates its immunosuppressive action at the NF-JB activation level. Although the precise mechanism by which UDCA or its conjugated forms inhibits an inflammatory response remain elusive, there is evidence that UDCA suppresses the microglial production of proinflammatory cytokines via the inactivation of the NF-JB pathway (56) . Furthermore, whereas some authors demonstrated that UDCA inhibits the translocation of NF-JB to the nucleus induced by diverse agents in different cell types (51, 57, 58) , Miura et al (59) showed that UDCA, although not affecting the cytoplasmic activation of NF-JB and its consequent nuclear translocation, interferes with its transcription function within the nucleus after an inflammatory stimulus. Our results showed that GUDCA is able to promote by itself the NF-JB nuclear translocation but does not change that by UCB. Thus, it seems likely that the prevention of UCB-induced cytokine release by GUDCA takes place downstream from NF-JB nuclear translocation.
Because a marked increase of TNF-> and IL-1A mRNA levels was observed in astrocytes exposed to UCB (9), we may assume that UCB regulates cytokine production at the transcriptional level by promoting its de novo synthesis. Here, we show that GUDCA is able to partially inhibit the UCB-stimulated TNF-> mRNA expression, but not that of IL-1A. Both TNF-> and IL-1A are translated as precursors that need proteolytic cleavage, also known as maturation, before being released from the cell (46) . Our results demonstrated that the intracellular levels of pro-TNF-> and pro-IL-1A decreased after exposure to UCB, whereas they markedly increased after astrocyte coincubation with GUDCA. Hence, whereas UCB promotes the maturation of the cytokine pro-forms and their consequent release, GUDCA acts downstream from the translated precursor proteins, inhibiting their activation.
TACE is a membrane-bound metalloprotease that processes the membrane-associated pro-TNF-> to active TNF->. Additionally, ICE, also known as caspase 1, is a member of the cysteine protease group that are involved in the apoptotic cascade (60) , which also presents the ability to cleave the inactive pro-IL-1A into the active form IL-1A. Our results demonstrate that both TACE and ICE activities increase in the presence of UCB, justifying the augmented release of the mature forms, but are markedly decreased by GUDCA because of its prevention of the cytokine posttranslational maturation.
Collectively, our data indicate that GUDCA and IL-10 differentially modulate astroglial reactivity to UCB. Whereas IL-10 only suppresses the release of cytokines from astrocytes exposed to UCB by blockade of NF-JB activation and cytokine mRNA expression, GUDCA plays a unique part in regulating both the UCB-induced loss of cell survival and the UCB-stimulating astroglial inflammatory response, the latter by inhibition of cytokine maturation and their release to the extracellular media. Moreover, the marked immunosuppressive action of both GUDCA and IL-10 on astrocytes suggests that the same agents may play an important role in regulating microglial reactivity to UCB. Consequently, GUDCA and IL-10 may prove to be interesting therapeutic drugs for the inhibition of UCB-induced astrocyte reactivity and demise associated with moderate to severe neonatal unconjugated hyperbilirubinemia.
